DE60135482D1 - Eukaryontische zellteilungsgene und deren verwendung in der diagnostik sowie in der behandlung von proliferativen erkrankungen - Google Patents
Eukaryontische zellteilungsgene und deren verwendung in der diagnostik sowie in der behandlung von proliferativen erkrankungenInfo
- Publication number
- DE60135482D1 DE60135482D1 DE60135482T DE60135482T DE60135482D1 DE 60135482 D1 DE60135482 D1 DE 60135482D1 DE 60135482 T DE60135482 T DE 60135482T DE 60135482 T DE60135482 T DE 60135482T DE 60135482 D1 DE60135482 D1 DE 60135482D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- proliferative diseases
- eukaryontic
- cell devices
- diagnostic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000002062 proliferating effect Effects 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 238000002955 isolation Methods 0.000 abstract 2
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 230000032823 cell division Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000007423 screening assay Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
- C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
- C07K14/43545—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24675000P | 2000-11-09 | 2000-11-09 | |
| PCT/EP2001/013034 WO2002038805A2 (en) | 2000-11-09 | 2001-11-09 | Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60135482D1 true DE60135482D1 (de) | 2008-10-02 |
Family
ID=22932039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60135482T Expired - Lifetime DE60135482D1 (de) | 2000-11-09 | 2001-11-09 | Eukaryontische zellteilungsgene und deren verwendung in der diagnostik sowie in der behandlung von proliferativen erkrankungen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7368248B2 (enExample) |
| EP (1) | EP1334123B1 (enExample) |
| JP (1) | JP2004526421A (enExample) |
| AT (1) | ATE405585T1 (enExample) |
| AU (2) | AU2002224838B9 (enExample) |
| CA (1) | CA2428438C (enExample) |
| DE (1) | DE60135482D1 (enExample) |
| DK (1) | DK1334123T3 (enExample) |
| WO (1) | WO2002038805A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| WO2003070918A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
| US7517864B2 (en) | 2001-05-18 | 2009-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| EP1432724A4 (en) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE |
| WO2005049846A2 (en) * | 2003-11-17 | 2005-06-02 | Crusade Laboratories Limited | Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer |
| ATE452188T1 (de) | 2004-02-10 | 2010-01-15 | Sirna Therapeutics Inc | Rna-interferenz-vermittelte hemmung der genexpression unter verwendung multifunktioneller sina (short interfering nucleic acid) |
| WO2005105157A2 (en) | 2004-04-23 | 2005-11-10 | The Trustees Of Columbia University In The City Ofnew York | INHIBITION OF HAIRLESS PROTEIN mRNA |
| US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
| US9708619B2 (en) | 2005-09-20 | 2017-07-18 | Basf Plant Science Gmbh | Methods for controlling gene expression using ta-siRNA |
| BRPI0809130A8 (pt) | 2007-03-21 | 2021-11-03 | Brookhaven Science Ass Llc | Composições combinadas hairpin-antissenso e métodos para modulação da expressão |
| CA2784783C (en) | 2009-12-18 | 2021-07-20 | Novartis Ag | Organic compositions to treat hsf1-related diseases |
| CA2789125A1 (en) | 2010-02-10 | 2011-08-18 | Novartis Ag | Methods and compounds for muscle growth |
| DK2632472T3 (en) | 2010-10-29 | 2018-03-19 | Sirna Therapeutics Inc | RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8910962D0 (en) | 1989-05-12 | 1989-06-28 | Natural Environment Res | Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells |
| US5162222A (en) | 1989-07-07 | 1992-11-10 | Guarino Linda A | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses |
| US5155037A (en) | 1989-08-04 | 1992-10-13 | The Texas A&M University System | Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems |
| CA2311201A1 (en) * | 1999-08-05 | 2001-02-05 | Genset S.A. | Ests and encoded human proteins |
-
2001
- 2001-11-09 DK DK01993708T patent/DK1334123T3/da active
- 2001-11-09 WO PCT/EP2001/013034 patent/WO2002038805A2/en not_active Ceased
- 2001-11-09 EP EP01993708A patent/EP1334123B1/en not_active Expired - Lifetime
- 2001-11-09 DE DE60135482T patent/DE60135482D1/de not_active Expired - Lifetime
- 2001-11-09 CA CA2428438A patent/CA2428438C/en not_active Expired - Fee Related
- 2001-11-09 JP JP2002542118A patent/JP2004526421A/ja active Pending
- 2001-11-09 US US10/415,657 patent/US7368248B2/en not_active Expired - Fee Related
- 2001-11-09 AT AT01993708T patent/ATE405585T1/de not_active IP Right Cessation
- 2001-11-09 AU AU2002224838A patent/AU2002224838B9/en not_active Ceased
- 2001-11-09 AU AU2483802A patent/AU2483802A/xx active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002224838B2 (en) | 2006-07-27 |
| JP2004526421A (ja) | 2004-09-02 |
| CA2428438A1 (en) | 2002-05-16 |
| EP1334123A2 (en) | 2003-08-13 |
| US20040048277A1 (en) | 2004-03-11 |
| AU2483802A (en) | 2002-05-21 |
| ATE405585T1 (de) | 2008-09-15 |
| CA2428438C (en) | 2012-09-25 |
| US7368248B2 (en) | 2008-05-06 |
| EP1334123B1 (en) | 2008-08-20 |
| WO2002038805A8 (en) | 2007-07-05 |
| AU2002224838B9 (en) | 2007-02-08 |
| WO2002038805A3 (en) | 2003-02-13 |
| WO2002038805A2 (en) | 2002-05-16 |
| DK1334123T3 (da) | 2009-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60135482D1 (de) | Eukaryontische zellteilungsgene und deren verwendung in der diagnostik sowie in der behandlung von proliferativen erkrankungen | |
| ATE415397T1 (de) | Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen | |
| ATE544748T1 (de) | Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen | |
| CY1116754T1 (el) | Παραγωγα νιτροκατεχολης ως αναστολεις της comt | |
| ATE325343T1 (de) | Diagnose und behandlung von arthritischen erkrankungen | |
| DE60328690D1 (de) | 1-aryl-4-substituierte piperazin-derivate zur verwendung als ccr1-antagonisten zur behandlung von entzündungen und immunerkrankungen | |
| WO2003009855A3 (de) | Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen | |
| DE60136826D1 (de) | Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs | |
| DE60019321D1 (de) | Verfahren zum screening von inhibitoren von asp2 | |
| DE60103171D1 (de) | Verfahren und verbindungen zur behandlung proliferativer erkrankungen | |
| DE60333901D1 (de) | Verfahren zur reduzierung der angiogenese | |
| ATE462702T1 (de) | Für die behandlung von entzündlichen krankheiten nützliche beta-carboline | |
| IL163951A (en) | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | |
| ATE352311T1 (de) | Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs | |
| EA200500934A1 (ru) | Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний | |
| ATE454465T1 (de) | In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie | |
| DE602004021363D1 (de) | Imidazotriazin verbindungen zur behandlung von krebserkrankungen | |
| ATE290857T1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
| DE602005007220D1 (de) | Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs | |
| BR0315344A (pt) | Métodos para prever edema como um efeito colateral do tratamento com drogas | |
| ATE456053T1 (de) | Na+, k+-atpase-expression bei zervixdysplasie und krebs | |
| ATE532509T1 (de) | Mittel zur hemmung des eintritts des hiv-virus | |
| EP1371729A3 (de) | Verwendungen von TFF3 bindenden Substanzen zur Diagnose und Behandlung von Krebserkrankungen | |
| WO2005025624A3 (en) | The use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferattive diseases | |
| ATE520653T1 (de) | Verbindungen, die den durch dna-schädigung induzierten g2-checkpoint des zellzyklus stilllegen und/oder die antikrebswirkung von dna- schädigenden behandlungen erhöhen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |